KALA BIO, INC. Deferred Revenue
KALA BIO, INC. (KALA) had Deferred Revenue of $4.19 million as of 2023-06-30, per its 10-Q filed 2023-08-04.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:DeferredRevenueCurrent · last filed 2024-03-29
- 2023-06-30: Deferred Revenue, Current $4.19M.
- 2023-03-31: Deferred Revenue, Current $4.19M.
- 2022-12-31: Deferred Revenue, Current $4.19M.
- 2022-09-30: Deferred Revenue, Current $3.41M.
| Period end | Deferred Revenue, Current |
|---|---|
| 2023-06-30 | $4.19M 10-Q · filed 2023-08-04 |
| 2023-03-31 | $4.19M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $4.19M 10-K · filed 2024-03-29 |
| 2022-09-30 | $3.41M 10-Q · filed 2022-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |